Baird Financial Group Inc. boosted its holdings in Iqvia Holdings Inc (NYSE:IQV) by 62.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 72,322 shares of the medical research company’s stock after buying an additional 27,678 shares during the period. Baird Financial Group Inc.’s holdings in Iqvia were worth $9,407,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Carillon Tower Advisers Inc. increased its position in Iqvia by 9.2% in the 2nd quarter. Carillon Tower Advisers Inc. now owns 258,241 shares of the medical research company’s stock worth $25,777,000 after buying an additional 21,846 shares during the period. Barings LLC increased its position in Iqvia by 74.1% in the 3rd quarter. Barings LLC now owns 18,962 shares of the medical research company’s stock worth $2,460,000 after buying an additional 8,070 shares during the period. Northern Trust Corp increased its position in Iqvia by 7.0% in the 2nd quarter. Northern Trust Corp now owns 1,877,470 shares of the medical research company’s stock worth $187,408,000 after buying an additional 122,260 shares during the period. Redpoint Investment Management Pty Ltd increased its position in Iqvia by 25.0% in the 2nd quarter. Redpoint Investment Management Pty Ltd now owns 13,657 shares of the medical research company’s stock worth $1,363,000 after buying an additional 2,732 shares during the period. Finally, BP PLC increased its position in Iqvia by 5.0% in the 3rd quarter. BP PLC now owns 21,000 shares of the medical research company’s stock worth $2,725,000 after buying an additional 1,000 shares during the period. 93.71% of the stock is currently owned by institutional investors.
IQV opened at $125.07 on Monday. The company has a market cap of $25.30 billion, a PE ratio of 28.69, a PEG ratio of 1.79 and a beta of 0.81. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 1.41. Iqvia Holdings Inc has a 1 year low of $91.57 and a 1 year high of $135.48.
Iqvia (NYSE:IQV) last announced its quarterly earnings results on Monday, October 22nd. The medical research company reported $1.42 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.03. The business had revenue of $2.59 billion for the quarter, compared to analyst estimates of $2.58 billion. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. As a group, research analysts predict that Iqvia Holdings Inc will post 5.13 earnings per share for the current year.
Several research analysts have commented on IQV shares. Zacks Investment Research raised Iqvia from a “hold” rating to a “buy” rating and set a $142.00 price target on the stock in a research report on Tuesday, October 23rd. UBS Group started coverage on Iqvia in a research report on Tuesday, October 9th. They set a “buy” rating on the stock. Argus set a $136.00 price objective on Iqvia and gave the company a “buy” rating in a research report on Thursday, August 23rd. Mizuho set a $120.00 price objective on Iqvia and gave the company a “hold” rating in a research report on Monday, August 6th. Finally, Piper Jaffray Companies boosted their price objective on Iqvia to $131.00 and gave the company a “neutral” rating in a research report on Tuesday, October 23rd. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Iqvia currently has a consensus rating of “Buy” and a consensus target price of $133.53.
In related news, Director John G. Danhakl sold 370,470 shares of the business’s stock in a transaction on Wednesday, September 12th. The stock was sold at an average price of $124.83, for a total value of $46,245,770.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John G. Danhakl sold 221,900 shares of the business’s stock in a transaction on Friday, September 7th. The shares were sold at an average price of $126.63, for a total value of $28,099,197.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 601,586 shares of company stock worth $75,510,422. 6.00% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/12/03/iqvia-holdings-inc-iqv-holdings-lifted-by-baird-financial-group-inc.html.
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
See Also: Cost of Capital Explained
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.